Literature DB >> 9325342

Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter.

M K Sievert1, A E Ruoho.   

Abstract

The full-length cDNA for the rat recombinant synaptic vesicle monoamine transporter (rVMAT2) containing a COOH-terminal polyhistidine epitope was engineered into baculovirus DNA for expression in Spodoptera frugiperda (Sf9) cells. Using this recombinant baculovirus and cultured Sf9 cells, rVMAT2 has been expressed to high levels and purified to >95% homogeneity using immobilized Ni2+-affinity chromatography followed by lectin (concanavalin A) chromatography. Purified transporter was photolabeled using [125I]-7-azido-8-iodoketanserin ([125I]AZIK) and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine ([125I]TBZ-AIPP). Both [125I]AZIK and [125I]TBZ-AIPP photoaffinity labeling of purified rVMAT2 were protectable by 10 microM tetrabenazine (TBZ), 10 microM 7-aminoketanserin, and 1 mM concentrations of the transporter substrates dopamine, norepinephrine, and serotonin. Radiolabeled peptides were generated using enzymatic and chemical methods, purified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and NH2-terminal microsequenced. Radiosequencing of [125I]AZIK-labeled rVMAT2 indicated derivatization of Lys-20 in the NH2 terminus, just prior to putative transmembrane domain 1 (TMD1). [125I]TBZ-AIPP derivatized a segment of rVMAT2 between Gly-408 and Cys-431 in TMD10 and 11. These data implicate juxtaposition of TMD1 and 10/11.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9325342     DOI: 10.1074/jbc.272.41.26049

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Authors:  Peter A Crooks; Guangrong Zheng; Ashish P Vartak; John P Culver; Fang Zheng; David B Horton; Linda P Dwoskin
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

2.  Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder.

Authors:  Falk W Lohoff; John P Dahl; Thomas N Ferraro; Steven E Arnold; Jürgen Gallinat; Thomas Sander; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

Review 3.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Authors:  Justin R Nickell; Kiran B Siripurapu; Ashish Vartak; Peter A Crooks; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

Review 4.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 5.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

6.  Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.

Authors:  Junchao Tong; Isabelle Boileau; Yoshiaki Furukawa; Li-Jan Chang; Alan A Wilson; Sylvain Houle; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-27       Impact factor: 6.200

7.  N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

Authors:  B Torres; A E Ruoho
Journal:  Neuroscience       Date:  2013-12-07       Impact factor: 3.590

8.  Probing the steroid binding domain-like I (SBDLI) of the sigma-1 receptor binding site using N-substituted photoaffinity labels.

Authors:  Dominique Fontanilla; Abdol R Hajipour; Arindam Pal; Uyen B Chu; Marty Arbabian; Arnold E Ruoho
Journal:  Biochemistry       Date:  2008-06-12       Impact factor: 3.162

9.  Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.

Authors:  Yelena Ugolev; Tali Segal; Dana Yaffe; Yael Gros; Shimon Schuldiner
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

10.  Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels.

Authors:  Michael K Sievert; Abdol R Hajipour; Arnold E Ruoho
Journal:  Anal Biochem       Date:  2007-05-03       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.